---
title: "Specialty Pharmacies Industry: Companies"
description: "Specialty pharmacies dispense high-cost drugs for complex conditions, such as cancer, multiple sclerosis and hepatitis."
canonical: https://www.getswoopr.com/stocks/industries/health-care/specialty-pharmacies/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Specialty Pharmacies Industry

## Direct Answer

Specialty pharmacies dispense high-cost drugs for complex conditions, such as cancer, multiple sclerosis and hepatitis, and provide patient support and insurance coordination. They earn margins on drug cost and fees from drug makers for data and adherence services.

## Industry Overview

Specialty Pharmacies sits within the health care sector. The first numbers to compare across companies here are prescription volume, gross profit per script and revenue mix by therapy. The outside forces that move them are listed under Primary Macro Drivers.

## Key Industry Metrics

- **Prescription volume**: Number of prescriptions dispensed for complex, high-cost drugs. Because each script carries high revenue, volume gains or losses, including from network exclusions, strongly affect results.
- **Gross profit per script**: Gross profit earned on each prescription after drug cost. It reflects reimbursement spread and fees, and compression here can offset volume growth.
- **Revenue mix by therapy**: Share of sales from areas such as cancer, immunology and rare disease. Mix matters because margins, patient support needs and exclusivity vary across therapy areas.
- **Manufacturer fees**: Payments from drug makers for data, adherence and distribution services. They add profit not tied to drug price, but depend on a manufacturer's channel decisions.
- **Share of payer-owned volume**: Share of specialty prescriptions dispensed by pharmacies owned by insurers or benefit managers. A rising share means payers steer more volume in-house, leaving independent pharmacies fewer referrals.

## Primary Macro Drivers

- **Growth of specialty drugs and biosimilars**: Rising use of high-cost drugs and biosimilars increases dollars dispensed and fees for adherence services, which shows in prescription volume and gross profit per script.
- **Payer and pharmacy benefit manager ownership of pharmacies**: When insurers or benefit managers own pharmacies, they route patients to their own sites, which moves volume and the share of payer-owned prescriptions.
- **Drug launch cadence**: New specialty drug launches add prescriptions and manufacturer fees, so the launch calendar moves volume and revenue mix by therapy.
- **Network exclusions**: Being excluded from a payer's pharmacy network removes access to that payer's members, which lowers prescription volume.

## Major Risks

- **Payer vertical integration**: Large insurers owning pharmacies can steer volume away from independent pharmacies; watch share of payer-owned volume and network access.
- **Reimbursement pressure and spread compression**: Lower payments to pharmacies for drugs shrink the gap between acquisition cost and reimbursement; watch gross profit per script.
- **Manufacturer channel changes**: Manufacturers may shift distribution to fewer pharmacies or direct to patients, which can remove drugs from a pharmacy's portfolio; watch revenue mix by therapy.
- **Regulatory audits**: Audits of billing and patient records can lead to repayments and penalties; watch legal notes and any reserves.

## Industry Characteristics

| Characteristic | Profile |
| --- | --- |
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | U.S. |

## Companies Associated with Specialty Pharmacies

The SEC's Standard Industrial Classification has no code that describes specialty pharmacies as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.

| Company | SEC classification | Revenue | Growth | Net margin | Year |
| --- | --- | --- | --- | --- | --- |
| [Cvs Health Corp](https://www.getswoopr.com/stocks/companies/cvs-health/) | Retail-Drug Stores And Proprietary Stores | $402.1 billion | 7.8% | 0.4% | FY 2025 |
| [Cigna Group](https://www.getswoopr.com/stocks/companies/cigna/) | Hospital & Medical Service Plans | $274.9 billion | 11.2% | 2.2% | FY 2025 |

Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the [company directory](https://www.getswoopr.com/stocks/companies/) and the [health care hub](https://www.getswoopr.com/stocks/industries/health-care/).

## Where to Go Next

The Specialty Pharmacies guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.

### More in Health Care

- [Health Care sector overview](https://www.getswoopr.com/stocks/industries/health-care/)
- [Surgical Robotics](https://www.getswoopr.com/stocks/industries/health-care/surgical-robotics/)
- [Specialty Pharmaceuticals](https://www.getswoopr.com/stocks/industries/health-care/specialty-pharmaceuticals/)
- [Surgical Supplies](https://www.getswoopr.com/stocks/industries/health-care/surgical-supplies/)
- [Skilled Nursing Facilities](https://www.getswoopr.com/stocks/industries/health-care/skilled-nursing-facilities/)
- [Telehealth](https://www.getswoopr.com/stocks/industries/health-care/telehealth/)
- [Senior Housing Operators](https://www.getswoopr.com/stocks/industries/health-care/senior-housing-operators/)
- [Urgent Care](https://www.getswoopr.com/stocks/industries/health-care/urgent-care/)
- [RNA Therapeutics](https://www.getswoopr.com/stocks/industries/health-care/rna-therapeutics/)

### Put it to work

- [How to analyze a stock](https://www.getswoopr.com/stocks/how-to-analyze-a-stock/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)
- [Company research](https://www.getswoopr.com/stocks/companies/)
- [All industries](https://www.getswoopr.com/stocks/industries/)

## Frequently Asked Questions

What are the main KPIs for the Specialty Pharmacies industry?

Key performance indicators for the Specialty Pharmacies industry include: Prescription volume, Gross profit per script, Revenue mix by therapy, Manufacturer fees, Share of payer-owned volume. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.

How cyclical is the Specialty Pharmacies industry?

The Specialty Pharmacies industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.

What are the biggest risks in the Specialty Pharmacies industry?

The primary risks for Specialty Pharmacies companies include: Payer vertical integration, Reimbursement pressure and spread compression, Manufacturer channel changes, Regulatory audits. Investors should assess each company's exposure to these factors and its track record of navigating them.

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).